Student Work

Sensitizing Medulloblastoma Cells to Stem Cell-Delivered TRAIL Using an HDAC Inhibitor

Public

Downloadable Content

open in viewer

Medulloblastoma (MB) patients suffer a poor prognosis and limitations of current treatments necessitate development of targeted therapies. TRAIL, a pro-apoptotic protein, targets tumor cells while sparing normal cells; however some tumors remain resistant, including the MB cell line DAOY. Mesenchymal stem cells (MSC) have been used for their tumoritropic properties to deliver apoptotic proteins. In this study, a TRAIL-expressing MSC line was investigated for a therapeutic effect on DAOYs in vitro, in the presence or absence of HDAC inhibitor MS-275. Results indicate that DAOYs respond to secreted TRAIL, and that MS-275 enhances this effect. Bioluminescent imaging shows that DAOYs survive and grow in an intracranial xenograft mouse model, allowing for future in vivo studies.

  • This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
Creator
Publisher
Identifier
  • E-project-011211-222811
Advisor
Year
  • 2011
Date created
  • 2011-01-12
Resource type
Major
Rights statement

Relations

In Collection:

Items

Items

Permanent link to this page: https://digital.wpi.edu/show/4j03d121p